Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Takeda reported a 2.4% increase in revenue for the quarter from the same period in 2021. It also announced it is dropping a cancer drug developed with Turnstone Biologics.
Sanofi released its second quarter financial report just two days after it announced its new diversity initiative with HBCU Howard University. Plus: Up-and-coming eczema biologics to shake Dupixent’s foothold
Money on the Move: A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases
BD, a leading global medical technology company, has expanded its BD MAX System platform to include a polymerase chain reaction (PCR) test for monkeypox.
COVID-19 has been remarkably profitable for Pfizer over the last year-and-a-half. The company’s revenue jumped by 47% to $27.7 billion compared to the same period in 2021.
Read on to learn about the different nursing positions available in the biopharmaceutical industry, as well as the skills and qualifications you need to be a successful biopharma nurse.
The result will be two independent, publicly traded companies: Labcorp and The Clinical Development Business offering Phase I-IV clinical trial management and technology to the biopharma industry.
City of Hope revealed that the oldest person living with HIV has achieved clinical remission after undergoing stem cell transplantation at the center more than three years ago.
FDA has approved GSK’s Benlysta (belimumab), making it the first biologic treatment for children ages 5 to 17 with lupus nephritis.
Eisai Inc. has appointed Thomas D. Fagan Jr. as VP for the U.S. Alzheimer’s Disease Commercial unit, which will be instrumental in growing the parent firms operations in the US.
The DESTINY-Breast04 trial introduces a new option for breast cancer diagnosis – HER2-low. The trial data received a standing ovation from thousands of oncologists at this year’s ASCO meeting.
The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.
